<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04439721</url>
  </required_header>
  <id_info>
    <org_study_id>PG-γδT-001</org_study_id>
    <nct_id>NCT04439721</nct_id>
  </id_info>
  <brief_title>γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse</brief_title>
  <acronym>γδT</acronym>
  <official_title>Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia
      Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      γδT cells belong to the innate immune system and have a powerful anti-tumor effect. Leukemia
      patients transplanted with allogeneic hematopoietic stem cells have an important role in
      controlling leukemia recurrence. Although adoptive immunotherapy using in vitro expanded γδT
      cells has achieved significant results in patients with solid tumors, infusion of donor γδT
      cells in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation to
      prevent leukemia recurrence has not been reported. . This clinical study intends to initially
      observe the safety and effectiveness of donor γδT cell infusion to prevent
      recurrence/refractory leukemia salvage allogeneic hematopoietic stem cell transplantation to
      further improve the transplantation effect of these patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the dose limiting toxicity (DLT)</measure>
    <time_frame>Frame 4 weeks after γδT infusion</time_frame>
    <description>Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale, version 5 and the number of patients experiencing DLT will be evaluated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>2 years after γδT infusion</time_frame>
    <description>Effectiveness after infusion of γδT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vivo persistence/expansion of infused γδT cell</measure>
    <time_frame>2 years after γδT infusion</time_frame>
    <description>Detection of infused γδT cell in the peripheral blood</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Leukemia, B-cell</condition>
  <arm_group>
    <arm_group_label>γδT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>γδT,Infusion,iv,0.5×10^6-8×10^7γδT /kg,once.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>γδT Cell infusion agent</intervention_name>
    <description>γδT</description>
    <arm_group_label>γδT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute leukemia patients undergoing salvage allogeneic hematopoietic stem cell
             transplantation

          -  Age 10-65,Any gender

          -  Expected lifetime&gt;3months

          -  ECOG 0-2

          -  DSA Negative

          -  Successful granulocyte implantation

          -  Liver and kidney function, heart and lung function meet the following
             requirements:①Creatinine≤1.5 ULN；②ALT/AST ≤5 ULN； ③Baseline oxygen saturation≥92%；
             ④Left ventricular ejection fraction≥50%

          -  Female subjects with fertility who had a negative pregnancy test within 48 hours
             before the infusion and were not breastfeeding; all subjects with fertility potential
             before enrolling in the study and throughout the study period until the last infusion
             Within 3 months, take adequate contraceptive measures

          -  Signing informed consent patients must be able to understand and be willing to
             participate in this study, and sign informed consent at the same time

        Exclusion Criteria:

          -  Donor HBsAg or HBcAb positive and HBV DNA titer test is not within the normal
             reference value; donor or patient HCV antibody positive and peripheral blood HCV RNA
             positive; donor or patient HIV antibody positive; donor syphilis test positive

          -  Active central nervous system disease

          -  BMI index&gt;35

          -  Allergic to DMSO

          -  Graft-versus-host disease

          -  Septic shock

          -  Systemic steroid therapy is required during cell infusion or cell collection, or there
             are conditions that researchers believe may require steroid therapy during blood
             collection or during infusion. In addition to cell collection or infusion, steroids
             for disease treatment are allowed, and inhaled steroids or hydrocortisone are also
             allowed for physiological replacement therapy in patients with adrenal insufficiency

          -  Participated in another clinical trial within 4 weeks before enrolling in the study,
             or intend to participate in another clinical trial throughout the study

          -  According to the judgment of the investigator, it does not meet the situation of cell
             preparation

          -  Circumstances considered by other researchers to be inappropriate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suning Chen, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology，The First Affiliaated Hospital Of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suning Chen, Ph.D</last_name>
    <phone>13814881746</phone>
    <email>chensuning@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaofei Yang, Ph.D</last_name>
    <phone>18962156841</phone>
    <email>yangxiaofei1977@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>No.188 Shizi Street</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaofei Yang, Ph.D</last_name>
      <phone>18962156841</phone>
      <email>yangxiaofei1977@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 16, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2020</study_first_posted>
  <last_update_submitted>June 17, 2020</last_update_submitted>
  <last_update_submitted_qc>June 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>γδT</keyword>
  <keyword>leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

